Therapeutic potential of mesenchymal stem cells in ocular degenerative disorders
Xiang Y., Zuo G., He X., Wang K., Zhu Y., Cheng S.
Clinical Trial on Immune Modulation, published in J Transl Med (2026) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- J Transl Med (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41736120
- PMCID
- PMC13041465
- DOI
- 10.1186/s12967-026-07878-9
Abstract (original English)
BACKGROUND: Mesenchymal stem cells (MSCs), with their regenerative, anti‑inflammatory, and immunomodulatory properties, represent a promising therapeutic strategy for degenerative retinal diseases. Current treatments fail to address core pathologies-such as inflammation, oxidative stress, and apoptosis-in conditions including diabetic retinopathy, age-related macular degeneration, retinitis pigmentosa, and glaucoma, underscoring the need for regenerative approaches. METHODS: This review summarizes the signaling pathways through which MSCs and their exosomes promote tissue repair and neuroprotection in ocular disorders. It evaluates published preclinical and clinical data to outline the current therapeutic applications, efficacy, and safety profiles of MSC-based therapies in ophthalmology. RESULTS: MSC-based interventions show potential in alleviating key pathogenic processes in retinal degeneration. Clinical trials indicate their ability to reduce inflammation, oxidative stress, and apoptotic cell death, thereby supporting retinal cell survival and function. These benefits are primarily mediated through paracrine signaling via extracellular vesicles such as exosomes. CONCLUSION: MSCs constitute a significant advance toward retinal repair and functional restoration. However, translation of these findings is hindered by the lack of standardized and regulated treatment protocols.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review
Systematic Review with a reported sample of 609 on Hair Loss, Immune Modulation, Autoimmune Research, published in Dermatol Reports (2026) — summary generated from the PubMed abstract.
- 2026
- n = 609
Dermatol Reports - Level ASystematic ReviewPubMed
Regeneration in Aesthetic Medicine: Mechanisms, Evidence, and Clinical Boundaries.
Systematic Review on Skin Aging, Immune Modulation, published in J Cosmet Dermatol (2026) — summary generated from the PubMed abstract.
- 2026
J Cosmet Dermatol - Level ASystematic ReviewEurope PMC
Molecular and Regenerative Effects of Platelet-Rich Plasma and Related Hemocomponents in Animal Models of Liver Injury-A Systematic Review
Systematic Review on Immune Modulation, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci - Level ASystematic ReviewPubMed
Stromal Vascular Fraction in Bone Healing: A Systematic Review of Clinical Evidence and Potential Implications in Skull Base Reconstruction and Cranioplasty.
Systematic Review with a reported sample of 214 on Chronic Wound, Immune Modulation, published in J Craniofac Surg (2026) — summary generated from the PubMed abstract.
- 2026
- n = 214
J Craniofac Surg - Level AMeta-analysisEurope PMC
The efficacy and safety of MSCs in GVHD prevention and the treatment of SR-aGVHD: a systematic review and meta-analysis of randomized controlled trials
Meta-analysis on Immune Modulation, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.
- 2026
Stem Cell Res Ther - Level ASystematic ReviewEurope PMC
Harnessing exosomes in dry eye disease: a triple threat approach
Systematic Review on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in BMC Ophthalmol (2026) — summary generated from the PubMed abstract.
- 2026
BMC Ophthalmol